Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 13  •  04:00PM ET
17.72
Dollar change
+0.17
Percentage change
0.94
%
CategoryGlobal or ExUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsGlobal Return% 1Y26.67% Total Holdings85 Perf Week-0.81%
SponsorWisdom Tree ETF Type Tagsequity Return% 3Y0.51% AUM2.29M Perf Month-2.43%
Fund Family Bond Type Tagsbiotechnology Return% 5Y- NAV/sh Perf Quarter5.50%
IndexWisdomTree BioRevolution Index Average Maturity Tags- Return% 10Y 52W High18.88 -6.12% Perf Half Y23.36%
Index Weighting Commodity Type Tags- Return% SI 52W Low11.20 58.24% Perf YTD5.03%
Active/Passive Quant Type Tags- Flows% 1M-13.49% Volatility1.04% 1.03% Perf Year20.98%
Dividend TTM0.77 (4.35%) ESG Type Tags- Flows% 3M-13.49% ATR (14)0.28 Perf 3Y-0.99%
Dividend Ex-DateDec 26, 2025 Dividend Type Sector/Theme Flows% YTD-13.49% RSI (14)47.71 Perf 5Y-
Dividend Gr. 3/5Y128.06% - Structure Type Region Flows% 1Y Beta1.07 Perf 10Y-
Expense0.45% Growth/Value SMA20-1.90% Flows% 3Y Rel Volume0.08 Prev Close17.56
Inverse/Leveraged Market Cap SMA50-0.06% Flows% 5Y Avg Volume1.54K Price17.72
IPOJun 03, 2021 Option/ShortYes / Yes SMA20014.72% Trades Volume127 Change0.94%
May-02-25 03:25AM
Apr-30-25 04:35AM
Apr-23-25 05:45AM
Apr-18-25 01:40PM
Apr-04-25 08:30AM
07:00AM Loading…
Apr-02-25 07:00AM
Apr-01-25 05:40AM
Mar-28-25 06:05AM
Mar-20-25 04:32PM
WisdomTree BioRevolution Fund seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index ("index"). The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.